Veliparib News and Research

RSS
SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

PARP inhibitor drugs can be structurally modified to better kill tumor cells

PARP inhibitor drugs can be structurally modified to better kill tumor cells

Intensive new combination therapy for ovarian cancer shows promising results

Intensive new combination therapy for ovarian cancer shows promising results

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Two genomic tests help identify most effective treatment for breast cancer patients

Two genomic tests help identify most effective treatment for breast cancer patients

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

I-SPY2 research initiative employs exciting new model for testing breast cancer drugs

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

Oral cancer drug improves outcomes in women with resistant gynecologic cancers

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Researchers test promising new breast cancer drugs

Researchers test promising new breast cancer drugs

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

Study could reveal whether breast cancer patients with BRCA mutations are responsive to Veliparib

Major study shoots for personalized breast cancer drugs

Major study shoots for personalized breast cancer drugs

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers